Sector ratings Vertex Pharmaceuticals Incorporated

Stocks

Market Closed - Nasdaq 00:00:00 03/10/2026 +04			5-day change	1st Jan Change
504.73 ^USD	-0.40%		-4.08%	+11.33%

09-28	UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating	MT
09-23	TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation
VERTEX PHARMACEUTICALS INCORPORATED	128B		AA
ELI LILLY AND COMPANY	1,019B		A
JOHNSON & JOHNSON	617B		BBB
ABBVIE INC.	464B		AAA		-
MERCK & CO., INC.	356B		A
ROCHE HOLDING AG	333B		AA
NOVARTIS AG	267B		AAA
ASTRAZENECA PLC	244B		A
AMGEN INC.	218B		A
GILEAD SCIENCES, INC.	179B		AA
NOVO NORDISK A/S	166B		BBB
PFIZER INC.	158B		A
BRISTOL-MYERS SQUIBB COMPANY	125B		A
MCKESSON CORPORATION	105B	-	AA	-	-
SANOFI	95.48B		A
GSK PLC	94.34B		AA
MODERNA, INC.	75.86B	-	BBB	-	-
REGENERON PHARMACEUTICALS, INC.	73.41B		BBB
MERCK KGAA	66.99B		AAA
CHUGAI PHARMACEUTICAL CO., LTD.	62.92B		AA
Average	242.42B		AA
Weighted average by Cap.			AA